PRAC recommendations on safety signals
PRAC recommendations on safety signals
PRAC recommendations on safety signals
PRAC recommendations on signals adopted at the 1-4 September 2025 PRAC meeting
New product information wording: extracts from PRAC recommendations on signals adopted at the 1-4 September 2025 PRAC
Human medicines European public assessment report (EPAR): Blitzima, rituximab, Date of authorisation: 13/07/2017, Revision: 24, Status: Authorised
Eligible patients and consumers organisations
A path to better include patients’ perspectives in the regulation of medicines
Human medicines European public assessment report (EPAR): Eliquis, apixaban, Date of authorisation: 18/05/2011, Revision: 37, Status: Authorised
Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, Date of authorisation: 11/02/2021, Revision: 19, Status: Authorised
Human medicines European public assessment report (EPAR): Xalkori, crizotinib, Date of authorisation: 23/10/2012, Revision: 39, Status: Authorised
Human medicines European public assessment report (EPAR): Ibandronic acid Accord, ibandronic acid, Date of authorisation: 18/11/2012, Revision: 17, Status: Authorised